Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection — FDA Drug Shortage
The FDA lists a drug shortage record for Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection (injection) from Merck Sharp & Dohme LLC with status To Be Discontinued. The shortage was first posted on Sep 9, 2026.
Shortage details
- Status
- To Be Discontinued
- Company
- Merck Sharp & Dohme LLC
- Package NDC
- 0006-3856-02
- Dosage Form
- Injection
- Presentation
- RECARBRIO, Injection, 500 mg/100 mL; 500 mg/100 mL; 250 mg/100 mL (NDC 0006-3856-02)
- Initial Posting
- Sep 9, 2026